论文部分内容阅读
目的探讨无创双水平气道正压通气(BiPAP)联合纳洛酮治疗慢性阻塞性肺病急性加重期(AECOPD)合并II型呼吸衰竭的疗效。方法将48例AECOPD合并II型呼吸衰竭的患者随机分成两组。治疗组,在常规抗感染、平喘、祛痰、BiPAP呼吸机等综合治疗的基础上,用盐酸纳络酮注射液0.8～1.2 mg加入0.9%氯化钠注射液或5%葡萄糖注射液250 ml中,静脉滴注,1次/d;对照组予以常规综合治疗。两组疗程均为3 d。观察治疗前、后的症状、体征及治疗前与治疗后的血气分析变化等指标评定疗效。结果治疗组在总疗效、改善症状、改善缺氧及二氧化碳潴留等方面疗效明显优于对照组(P<0.05)。结论 BiPAP联合纳洛酮治疗AECOPD合并II型呼吸衰竭的疗效肯定,具有较好的临床应用价值。
Objective To investigate the efficacy of noninvasive bi-level positive airway pressure (BiPAP) combined with naloxone in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and type II respiratory failure. Methods 48 patients with AECOPD combined with type II respiratory failure were randomly divided into two groups. The treatment group was treated with 0.8-1.2 mg naloxone hydrochloride injection 0.9% sodium chloride injection or 5% glucose injection 250 on the basis of general anti-infective, antiasthmatic, expectorant, BiPAP ventilator and other comprehensive treatment. ml, intravenous infusion, 1 / d; control group to conventional treatment. The two courses of treatment were 3 d. Observed before and after treatment of symptoms and signs and treatment before and after treatment of blood gas changes in indicators such as assessment of efficacy. Results The treatment group was significantly better than the control group in overall efficacy, improvement of symptoms, improvement of hypoxia and carbon dioxide retention (P <0.05). Conclusion BiPAP combined with naloxone in the treatment of AECOPD combined with type II respiratory failure is positive, with good clinical value.